Trial Profile
A Phase 2, Randomized, Double-Blind, Parallel-Group Study to Assess the Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With Usual Type Vulvar Intraepithelial Neoplasia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Omiganan (Primary) ; Omiganan (Primary)
- Indications Vulvar intraepithelial neoplasia
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Cutanea Life Sciences
- 22 Nov 2019 Results assessing safety and tolerability and explore pharmacodynamics and efficacy of omiganan in external anogenital warts published in the British Journal of Clinical Pharmacology
- 01 Aug 2017 Status changed from active, no longer recruiting to completed.
- 21 Sep 2016 Status changed from recruiting to active, no longer recruiting.